Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $14.6 million.

  • Mereo BioPharma Group's Total Non-Current Liabilities fell 58.13% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 58.13%. This contributed to the annual value of $14.6 million for FY2024, which is 3.93% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Total Non-Current Liabilities stood at $14.6 million for FY2024, which was down 3.93% from $15.2 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Total Non-Current Liabilities peaked at $89.1 million during FY2020, and registered a low of $14.6 million during FY2024.
  • Its 3-year average for Total Non-Current Liabilities is $18.3 million, with a median of $15.2 million in 2023.
  • Data for Mereo BioPharma Group's Total Non-Current Liabilities shows a maximum YoY tumbled of 60.84% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Total Non-Current Liabilities stood at $89.1 million in 2020, then plummeted by 60.84% to $34.9 million in 2021, then dropped by 27.92% to $25.1 million in 2022, then slumped by 39.55% to $15.2 million in 2023, then dropped by 3.93% to $14.6 million in 2024.